Olufunmilayo H. Obisesan

Olufunmilayo H. Obisesan

Auto-generated profile, based on publicly available information

Olufunmilayo H. Obisesan

Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD, USA; Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
OOOlufunmilayo H. Obisesan
Olufunmilayo H. Obisesan
MMMohammadhassan Mirbolouk
Mohammadhassan Mirbolouk
AOAlbert D. Osei
Albert D. Osei
OOOlusola A. Orimoloye
Olusola A. Orimoloye
SUS. M. Iftekhar Uddin
S. M. Iftekhar Uddin
MBMichael J. Blaha
Michael J. Blaha
Electronic cigarettes (e-cigarettes) were introduced into the US market more than a decade ago as an alternative to combustible cigarettes.1-3 They are marketed as less harmful nicotine delivery devices; however, their contents are largely unregulated and vary widely, with nicotine concentrations ranging from 0 to 59 mg/mL.4,5 Many products also contain potentially toxic metals, such as arsenic and lead, as well as propylene glycol. When used, e-cigarettes may generate volatile organic compounds, including acetaldehyde and formaldehyde, especially at high temperatures.4,6

2 March 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
APAllison W. Peng
Allison W. Peng
ZDZeina A. Dardari
Zeina A. Dardari
RBRoger S. Blumenthal
Roger S. Blumenthal
ODOmar Dzaye
Omar Dzaye
OOOlufunmilayo H. Obisesan
Olufunmilayo H. Obisesan
MBMichael J. Blaha
Michael J. Blaha
Background: There are limited data on the unique cardiovascular disease (CVD), non-CVD, and mortality risks of primary prevention individuals with very high coronary artery calcium (CAC; ≥1000), especially compared with rates observed in secondary prevention populations. Methods: Our study population consisted of 6814 ethnically diverse individuals 45 to 84 years of age who were free of known CVD from MESA (Multi-Ethnic Study of Atherosclerosis), a prospective, observational, community-based cohort. Mean follow-up time was 13.6±4.4 years. Hazard ratios of CAC ≥1000 were compared with both CAC 0 and CAC 400 to 999 for CVD, non-CVD, and mortality outcomes with the use of Cox proportional hazards regression adjusted for age, sex, and traditional risk factors. Using a sex-adjusted logarithmic model, we calculated event rates in MESA as a function of CAC and compared them with those observed in the placebo group of stable secondary prevention patients in the FOURIER clinical trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Results: Compared with CAC 400 to 999, those with CAC ≥1000 (n=257) had a greater mean number of coronary vessels with CAC (3.4±0.5), greater total area of CAC (586.5±275.2 mm 2 ), similar CAC density, and more extensive extracoronary calcification. After full adjustment, CAC ≥1000 demonstrated a 4.71- (3.63–6.11), 7.57- (5.50–10.42), 4.86-(3.32–7.11), and 1.94-fold (1.57–2.41) increased risk for all CVD events, all coronary heart disease events, hard coronary heart disease events, and all-cause mortality, respectively, compared with CAC 0 and a 1.65- (1.25–2.16), 1.66- (1.22–2.25), 1.51- (1.03–2.23), and 1.34-fold (1.05–1.71) increased risk compared with CAC 400 to 999. With increasing CAC, hazard ratios increased for all event types, with no apparent upper CAC threshold. CAC ≥1000 was associated with a 1.95- (1.57–2.41) and 1.43-fold (1.12–1.83) increased risk for a first non-CVD event compared with CAC 0 and CAC 400 to 999, respectively. CAC 1000 corresponded to an annualized 3-point major adverse cardiovascular event rate of 3.4 per 100 person-years, similar to that of the total FOURIER population (3.3) and higher than those of the lower-risk FOURIER subgroups. Conclusions: Individuals with very high CAC (≥1000) are a unique population at substantially higher risk for CVD events, non-CVD outcomes, and mortality than those with lower CAC, with 3-point major adverse cardiovascular event rates similar to those of a stable treated secondary prevention population. Future guidelines should consider a less distinct stratification algorithm between primary and secondary prevention patients in guiding aggressive preventive pharmacotherapy.

1 February 2021 in Radiology: Cardiothoracic Imaging
Verified
Journal Article
Closed access
OOOlufunmilayo H. Obisesan
Olufunmilayo H. Obisesan
AOAlbert D. Osei
Albert D. Osei
SUS.M. Iftekhar Uddin
S.M. Iftekhar Uddin
ODOmar Dzaye
Omar Dzaye
MBMichael J. Blaha
Michael J. Blaha
The increased use of coronary artery calcium (CAC) on both gated and nongated CT scans necessitates a summary of recent updates in CAC interpretation and recommendations for more unified CAC report... Coronary artery calcium (CAC) is a marker of overall coronary atherosclerotic burden in an individual. As such, it is an important tool in cardiovascular risk stratification and preventive treatmen...

1 December 2020 in Radiology: Cardiothoracic Imaging
Verified
Journal Article
Closed access
SASiegfried Adelhoefer
Siegfried Adelhoefer
SUS. M. Iftekhar Uddin
S. M. Iftekhar Uddin
AOAlbert D. Osei
Albert D. Osei
OOOlufunmilayo H. Obisesan
Olufunmilayo H. Obisesan
MBMichael J. Blaha
Michael J. Blaha
ODOmar Dzaye
Omar Dzaye
Coronary artery calcium is the single most reliable predictor for long-term, cause-specific mortality across patient subgroups based on age, ethnicity, sex, and risk factor burden, proving its cruc... Coronary artery calcium (CAC) is a highly specific marker for coronary atherosclerosis. The CAC Consortium, a multicenter, retrospective, real-world cohort study, was established to investigate the...

1 August 2020 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
OOOlufunmilayo H. Obisesan
Olufunmilayo H. Obisesan
AOAlbert D. Osei
Albert D. Osei
SUS.M. Iftekhar Uddin
S.M. Iftekhar Uddin
ODOmar Dzaye
Omar Dzaye
MCMiguel Cainzos-Achirica
Miguel Cainzos-Achirica
MBMichael J. Blaha
Michael J. Blaha

1 December 2021 in Preventive Medicine
Verified
Journal Article
Closed access
EBEllen Boakye
Ellen Boakye
OOOlufunmilayo H. Obisesan
Olufunmilayo H. Obisesan
SUS.M. Iftekhar Uddin
S.M. Iftekhar Uddin
OSOmar El Shahawy
Omar El Shahawy
ODOmar Dzaye
Omar Dzaye
MBMichael J. Blaha
Michael J. Blaha